Roche Relabels Accutane After Independent Review Of MedWatch Reports
Executive Summary
A dozen MedWatch reports of Accutane patients experiencing depression after re-initiation of therapy with isotretinoin contributed to the relabeling decision announced by FDA on Feb. 25.